Promising new combo targets tough head and neck cancer
NCT ID NCT07628855
First seen Jun 07, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—as a first treatment for advanced head and neck squamous cell carcinoma. It is for patients whose cancer has returned or spread and who cannot tolerate platinum-based chemotherapy. The study will enroll 30 participants to see if the combo can shrink tumors and how safe it is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
becotatug vedotin (targeted cancer drug) combined with pucotenlimab (immunotherapy)
What this could lead to
If successful, this could offer a new first-line treatment option for people with advanced head and neck cancer who cannot tolerate standard platinum chemotherapy.
What could go wrong
This is a small, early-phase trial (30 people) with no control group, so results may not be definitive. The drug combination may cause side effects or fail to shrink tumors in many patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.